

**SUPPLEMENTAL MATERIAL****Supplemental Table****Suppl. Table 1. Clinical characteristics before discharge in patients with and without all-cause mortality**

	<b>All-cause mortality</b>		<b>P value</b> (- vs. +)
	<b>- (n = 464)</b>	<b>+ (n = 88)</b>	
<b>Age, years</b>	<b>80 ± 9</b>	<b>85 ± 7</b>	<b>&lt;0.001</b>
<b>Male sex, n (%)</b>	<b>216 (47)</b>	<b>39 (44)</b>	<b>0.700</b>
<b>Systolic blood pressure, mmHg</b>	<b>120 ± 17</b>	<b>120 ± 19</b>	<b>0.896</b>
<b>Diastolic blood pressure, mmHg</b>	<b>66 ± 11</b>	<b>65 ± 11</b>	<b>0.731</b>
<b>Heart rate, bpm</b>	<b>71 ± 13</b>	<b>74 ± 14</b>	<b>0.085</b>
<b>Atrial fibrillation, n (%)</b>	<b>166 (36)</b>	<b>34 (39)</b>	<b>0.608</b>
<b>Chronic obstructive pulmonary disease, n (%)</b>	<b>27 (6)</b>	<b>8 (9)</b>	<b>0.248</b>
<b>Coronary artery disease, n (%)</b>	<b>96 (21)</b>	<b>22 (25)</b>	<b>0.365</b>
<b>Diabetes mellitus, n (%)</b>	<b>165 (36)</b>	<b>29 (33)</b>	<b>0.638</b>
<b>Dyslipidemia, n (%)</b>	<b>203 (44)</b>	<b>31 (35)</b>	<b>0.138</b>
<b>Hypertension, n (%)</b>	<b>404 (87)</b>	<b>74 (84)</b>	<b>0.452</b>
<b>Laboratory data</b>			
<b>Albumin, g/dL</b>	<b>3.4 ± 0.4</b>	<b>3.1 ± 0.5</b>	<b>&lt;0.001</b>
<b>eGFR, mL/min/1.73 m<sup>2</sup></b>	<b>43.1 ± 18.6</b>	<b>40.3 ± 21.0</b>	<b>0.210</b>
<b>Hemoglobin, g/dL</b>	<b>11.5 ± 2.0</b>	<b>10.7 ± 1.8</b>	<b>&lt;0.001</b>
<b>N-terminal pro-brain natriuretic peptide, pg/mL</b>	<b>2309 ± 4834</b>	<b>4479 ± 10758</b>	<b>0.004</b>
<b>Echocardiographic data</b>			
<b>LAD, mm</b>	<b>44 ± 8</b>	<b>44 ± 8</b>	<b>0.808</b>
<b>LAVI, mL/m<sup>2</sup></b>	<b>53 ± 24</b>	<b>59 ± 29</b>	<b>0.075</b>
<b>LVEDVI, mL/m<sup>2</sup></b>	<b>54 ± 20</b>	<b>56 ± 22</b>	<b>0.401</b>
<b>LVESVI, mL/m<sup>2</sup></b>	<b>21 ± 11</b>	<b>23 ± 13</b>	<b>0.262</b>
<b>SVI, mL/m<sup>2</sup></b>	<b>32 ± 12</b>	<b>33 ± 12</b>	<b>0.702</b>
<b>SV/LAV</b>	<b>0.72 ± 0.37</b>	<b>0.69 ± 0.48</b>	<b>0.608</b>
<b>LVEF, %</b>	<b>61 ± 8</b>	<b>60 ± 8</b>	<b>0.319</b>
<b>TAPSE, mm</b>	<b>17.8 ± 4.4</b>	<b>16.8 ± 4.7</b>	<b>0.071</b>
<b>E/e'</b>	<b>13.4 ± 5.3</b>	<b>15.6 ± 5.9</b>	<b>&lt;0.001</b>
<b>Ed/Ea</b>	<b>0.125 ± 0.050</b>	<b>0.147 ± 0.057</b>	<b>&lt;0.001</b>
<b>Medications</b>			

Beta-blockers, n (%)	252 (54)	51 (58)	0.528
Calcium-channel blockers, n (%)	242 (52)	48 (55)	0.680
Diuretics, n (%)	385 (83)	76 (86)	0.432
RAAS inhibitors, n (%)	344 (74)	64 (73)	0.782
Statins, n (%)	158 (34)	29 (33)	0.842

Values are presented as means  $\pm$  standard deviations or numbers (%).

eGFR, estimated glomerular filtration rate; LAD, left atrial diameter;

LAVI, left atrial volume index; LVEDVI, left ventricular end-diastolic volume index;

LVESVI, left ventricular end-systolic volume index; SVI, stroke volume index;


SV, stroke volume; LAV, left atrial volume; LVEF, left ventricular ejection fraction;

TAPSE, tricuspid annular plane systolic excursion;

Ed, diastolic elastance; Ea, arterial elastance;

RAAS, renin-angiotensin-aldosterone system

## Supplemental Figure



**Suppl. Figure 1.** Kaplan–Meier survival curve analysis of patients with heart failure with preserved ejection fraction shows that the ratio of stroke volume (SV) to left atrial volume (LAV), N-terminal pro-brain natriuretic peptide (NT-proBNP), albumin, hemoglobin, and estimated glomerular filtration rate (eGFR), but not left atrial volume index (LAVI), are significant prognostic factors for all-cause mortality during the whole follow-up time.